Silverback Therapeutics Inc

NASDAQ SPRY

Data sourced from

and

Download Data

Silverback Therapeutics Inc Stock-Based Compensation 2 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: 524.62%

Silverback Therapeutics Inc Stock-Based Compensation 2 year CAGR is 524.62% for the Trailing 12 Months (TTM) ending March 31, 2024. Stock-Based Compensation represents the cost of employee compensation provided in the form of equity-based instruments, such as stock options or restricted stock units. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Silverback Therapeutics Inc Stock-Based Compensation for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 7.83 M, a 2,865.53% change year over year.
Silverback Therapeutics Inc Stock-Based Compensation for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 264.00 K.

NASDAQ: SPRY

Silverback Therapeutics Inc

CEO	Mr. Richard Lowenthal M.B.A., M.S., MSMSEL
IPO Date	Dec. 4, 2020
Location	United States
Headquarters	3525 Del Mar Heights Road, San Diego, CA, United States, 92130
Employees	24
Sector	Healthcare
Industry	Biotechnology

Description

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Key trends